Mrdenovic, Stefan
Wang, Yanping
Yin, Lijuan
Chu, Gina Chia-Yi
Ou, Yan
Lewis, Michael S.
Heffer, Marija
Posadas, Edwin M.
Zhau, Haiyen E.
Chung, Leland W. K.
Edderkaoui, Mouad
Pandol, Stephen J.
Wang, Ruoxiang
Zhang, Yi
Funding for this research was provided by:
Phileoever Foundation grant
U.S. Department of Defense (PA 210175, PA 210175)
National Institutes of Health (R21CA256419, R21CA256419)
Cedars‐Sinai CTSI grant (UL1TR001881)
Article History
Received: 31 October 2022
Accepted: 24 April 2023
First Online: 2 June 2023
Declarations
:
: DZ‐CIS is licensed to DaZen Theranostics, Inc., where Leland W. K. Chung is currently serving as the Chairman of the Board and Chief Scientist for the development of one of the licensed lead compounds from laboratory to the clinic and for which Stefan Mrdenovic, Haiyen E. Zhau, Yi Zhang, Ruoxiang Wang, and Gina Chia‐Yi Chu are shareholders. Leland W. K. Chung also has a patent pending (US 2016/0310604 A1). All other authors, Yanping Wang, Lijuan Yin, Yan Ou, Michael S. Lewis, Marija Heffer, Edwin M. Posadas, Mouad Edderkaoui and Stephen J. Pandol, declared that they have no competing interests.
: The animal study approval was obtained from the Institutional Animal Care and Use Committee (IACUC), Cedars-Sinai Medical Center (Protocols #6403 and #10063). All animal experiments were performed in accordance with the guidance and regulations. All methods were carried out in accordance with ARRIVE guidelines (ExternalRef removed) for the reporting of animal experiments. The ex vivo culture of a ccRCC surgical tumor specimen was approved by the Institutional Review Board (#Pro00031870) of the Cedars-Sinai Medical Center. Informed consent was obtained from the subject. All methods were carried out in accordance with the IRB guidelines and regulations.
: Not applicable.